Abstract Details

Title Point Prevalence of Causal Risk Factors and Treatment Utilization in Distal Sensory Polyneuropathy: A Retrospective Analysis of Commercial and Medicare Claims Data

Topic Pain

Presentation(s) P4 - Poster Session 4 (5:00 PM-6:00 PM)

Poster/Presentation
Number 7-003

Objective This analysis aimed to investigate the point prevalence, causal risk factors, and treatment utilization in distal sensory polyneuropathy (DSP).

Background DSP is a common neurologic disease characterized by pain and/or other symptoms that can stem from multiple causes of nerve injury.

Design/Methods In this retrospective cohort analysis, adults with ≥1 DSP claim were identified from large commercial and Medicare Advantage health plans from January 2017 through February 2023, using Optum^® Clinformatics Data Mart. Patients were categorized into cohorts by DSP type (diabetic, nondiabetic, or mixed), and their use of medical and pharmacy services, including indicators of painful DSP, were analyzed over 12 months.

Results Approximately 2 million adults had DSP claims. Diabetes was the most common cause (55.9% of patients), yet 37.4% of these individuals also had claims associated with nondiabetic causes of DSP (mixed). Approximately 25.0% of patients had idiopathic DSP claims and 43.9% had “unspecified” DSP claims. Antihypertensives and analgesics were the most commonly prescribed medications. Among the analgesics, opioids and gabapentinoids were most frequently used (40.7% and 38.1% of patients, respectively). Patients with mixed DSP tended to have higher pain prevalence, comorbidity rates, analgesics, and select nonpharmacologic treatments than those with diabetic or nondiabetic causes of DSP. The presence of pain in each of these cohorts increased the rates of medication use (for pain and other conditions) and other pain, mental health, and sleep disturbance diagnoses.

Conclusions This analysis examined risk factors for DSP and its prevalence in real-world clinical practice. Data are limited due to the common use of nondescript/unspecified codes. However, there appears to be a cumulative burden when multiple risk factors are present as illustrated by the higher rates of analgesic and nonpharmacologic pain treatments and comorbid conditions regardless of whether diabetes was present.

Authors/Disclosures
John Markman, MD, FAAN (Eli Lilly) PRESENTER	Dr. Markman has received personal compensation for serving as an employee of Eli LIlly.
Rebecca L. Robinson, MS (Eli Lilly and Company)	Mrs. Robinson has received personal compensation for serving as an employee of Eli Lilly and Company. Mrs. Robinson has stock in Eli Lilly and Company.
Margaret Hoyt, PhD (Eli Lilly and Co.)	Dr. Hoyt has received personal compensation for serving as an employee of Eli Lilly and Co.. Dr. Hoyt has stock in Eli Lilly and Co..
Virginia L. Stauffer, PharmD	Dr. Stauffer has received personal compensation for serving as an employee of Eli Lilly and Company. Dr. Stauffer has stock in Eli Lilly and Company.
Todd D. Levine, MD (Honor Health)	Dr. Levine has received personal compensation for serving as an employee of CND life sciences . Dr. Levine has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Nufactor. Dr. Levine has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for PNA. Dr. Levine has or had stock in CND Life Sciences.Dr. Levine has or had stock in Corinthian reference lab.

��ɫ��

��ɫ��